Phase I study of [111In]-FPI-2107 in EGFR mutation-positive NSCLC

Trial Identifier:	D8650C00002
Sponsor:	AstraZeneca
Start Date:	February 2026
Primary Completion Date:	July 2026
Study Completion Date:	July 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	Beijing, CN, 100142
CN	Shandong, CN
CN	Wuhan, CN, 430022

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.